Posted: April 13, 2025 at 2:46 am
GLASGOW, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- There are relatively few testosterone boosters with natural substances that have been clinically shown to increase testosterone levels without producing side effects.
Visit link:
TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe?
Posted: April 13, 2025 at 2:46 am
Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate
Here is the original post:
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and...
Posted: April 13, 2025 at 2:46 am
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 20 new employees in restricted stock units for an aggregate of 77,652 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
Read this article:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Posted: April 13, 2025 at 2:46 am
April 11, 2025, 10:01 PM CET
Read this article:
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Posted: April 13, 2025 at 2:46 am
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Posted: April 13, 2025 at 2:46 am
Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy
Posted: April 13, 2025 at 2:46 am
Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its ordinary shares was below $1.00 per share for the last 30 consecutive business days.
Visit link:
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Posted: April 13, 2025 at 2:46 am
Châtillon, France, April 11, 2025
Posted: April 13, 2025 at 2:46 am
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press release issued today by Future Pak, LLC (“Future Pak”) regarding its proposals to acquire the Company.
Posted: April 13, 2025 at 2:46 am
Not for distribution to U.S. news wire services or dissemination in the United States
See the original post here:
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
